Business Description
Assembly Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US0453961080
Total Employee Number:
73Description
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 90.97 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.19 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.2 | |||||
Beneish M-Score | -0.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 64.2 | |||||
3-Year EPS without NRI Growth Rate | 71.2 | |||||
3-Year FCF Growth Rate | 44.1 | |||||
3-Year Book Growth Rate | -13.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -77.85 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.95 | |||||
9-Day RSI | 58.13 | |||||
14-Day RSI | 57.06 | |||||
3-1 Month Momentum % | -23.16 | |||||
6-1 Month Momentum % | -27.73 | |||||
12-1 Month Momentum % | 30.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.65 | |||||
Quick Ratio | 6.65 | |||||
Cash Ratio | 6.47 | |||||
Days Sales Outstanding | 4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -57.3 | |||||
Shareholder Yield % | -30.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -19.05 | |||||
Net Margin % | -8.98 | |||||
EBITDA Margin % | -18.88 | |||||
FCF Margin % | -56.47 | |||||
OCF Margin % | -56.44 | |||||
ROE % | -5.04 | |||||
ROA % | -3.5 | |||||
ROIC % | -29.63 | |||||
3-Year ROIIC % | 243.91 | |||||
ROC (Joel Greenblatt) % | -471.56 | |||||
ROCE % | -9.93 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.29 | |||||
PB Ratio | 2.23 | |||||
Price-to-Tangible-Book | 2.23 | |||||
EV-to-EBIT | -24.23 | |||||
EV-to-EBITDA | -24.45 | |||||
EV-to-Forward-EBITDA | 11.16 | |||||
EV-to-Revenue | 4.62 | |||||
EV-to-Forward-Revenue | 2.96 | |||||
EV-to-FCF | -8.25 | |||||
| Price-to-Net-Current-Asset-Value | 2.26 | |||||
| Price-to-Net-Cash | 2.33 | |||||
Earnings Yield (Greenblatt) % | -4.13 | |||||
FCF Yield % | -7.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Assembly Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 60.911 | ||
| EPS (TTM) (€) | -1.043 | ||
| Beta | 0.3724 | ||
| 3-Year Sharpe Ratio | 0.68 | ||
| 3-Year Sortino Ratio | 1.21 | ||
| Volatility % | 59.62 | ||
| 14-Day RSI | 57.06 | ||
| 14-Day ATR (€) | 1.191685 | ||
| 20-Day SMA (€) | 22.5875 | ||
| 12-1 Month Momentum % | 30.03 | ||
| 52-Week Range (€) | 14.55 - 33.8 | ||
| Shares Outstanding (Mil) | 19.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Assembly Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Assembly Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 16:09 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 26 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 08:40 | 19.52 (-4.08%) | ||
| General meeting for 2026 | 2026-06-04 08:00 | 21.00 (+1.69%) | ||
| Guidance call for 2026 | 2026-06-03 16:20 | 21.05 (-8.68%) | ||
| Guidance call for 2026 | 2026-05-13 16:35 | 26.05 (+2.56%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 26.40 (+3.94%) | ||
| Annual report for 2025 | 2026-03-19 | 23.90 (-2.85%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 23.90 (-2.85%) | ||
| ABI-1179 and ABI-5366 Interim Phase 1b Results Update | 2025-12-08 18:00 | 29.60 (+1.72%) |
Show
Entries
Assembly Biosciences Inc Frequently Asked Questions
What is Assembly Biosciences Inc(STU:V7B)'s stock price today?
The current price of STU:V7B is €24.00. The 52 week high of STU:V7B is €33.80 and 52 week low is €14.55.
When is next earnings date of Assembly Biosciences Inc(STU:V7B)?
The next earnings date of Assembly Biosciences Inc(STU:V7B) is 2026-08-06 Est..
Does Assembly Biosciences Inc(STU:V7B) pay dividends? If so, how much?
Assembly Biosciences Inc(STU:V7B) does not pay dividend.
Press Release
Articles on Assembly Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers